Modified guidelines impact on antibiotic use and costs: Duration of treatment for pneumonia in a neurosurgical ICU is reduced

Journal of Antimicrobial Chemotherapy

Volumn 59, Issue 6, 2007, Pages 1148-1154

  Meyer, Elisabeth ^a   Buttler, Juergen ^a   Schneider, Christian ^a   Strehl, Egid ^a   Schroeren Boersch, Barbara ^a   Gastmeier, Petra ^b,c   Ruden, Henning ^c,d   Zentner, Josef ^a   Daschner, Franz D ^a,c   Schwab, Frank ^c,d  

^a UNIVERSITY OF FREIBURG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c National Reference Centre for Surveillance of Nosocomial Infections   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Costs; Duration of antibiotic treatment; Intensive care units; Interrupted time series; Segmented regression analysis

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAMASE INHIBITOR; CARBAPENEM; CARBAPENEM DERIVATIVE; CEFOTIAM; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; ERYTHROMYCIN; GENTAMICIN; GLYCOPEPTIDE; IMIDAZOLE DERIVATIVE; METRONIDAZOLE; OXACILLIN; PENICILLIN DERIVATIVE; PENICILLIN G; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TAZOBACTAM; VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL PNEUMONIA; CALCULATION; COMMUNITY ACQUIRED PNEUMONIA; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DEATH; DEVICE INFECTION; DRUG COST; DRUG USE; HOSPITAL INFECTION; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEUROSURGERY; NONHUMAN; PRACTICE GUIDELINE; REGRESSION ANALYSIS; RESPIRATORY TRACT INFECTION; TIME SERIES ANALYSIS; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; COST CONTROL; COSTS AND COST ANALYSIS; DATA COLLECTION; DATA INTERPRETATION, STATISTICAL; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; GUIDELINES; HUMANS; INTENSIVE CARE; LENGTH OF STAY; NEUROSURGICAL PROCEDURES; PNEUMONIA, VENTILATOR-ASSOCIATED; REGRESSION ANALYSIS;

EID: 34447545620     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm088     Document Type: Article

References (20)

1. Goldmann DA, Weinstein RA, Wenzel RP et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. A challenge to hospital leadership. JAMA 1996; 275: 234-40.
2. John JF Jr, Fishman NO. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. Clin Infect Dis 1997; 24: 471-85.
3. Ramsay C, Brown E, Hartman G et al. Room for improvement: A systematic review of the quality of evaluations of interventions to improve hospital antibiotic prescribing. J Antimicrob Chemother 2003; 52: 764-71.
4. Chastre J, Wolff M, Fagon JY et al. Comparison of 8 versus 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial. JAMA 2003; 290: 2588-98.
5. DIN 58940-4. Medical Microbiology - Methods for the Determination of Susceptibility of Pathogens (Except Mycobacteria) to Antimicrobial Agents. Part 4: Evaluation Classes of the Minimum Inhibitory Concentration. Berlin: Beuth Verlag, 1998; 1-11.
6. Gastmeier P, Geffers C, Sohr D et al. Five years working with the German nosocomial infection surveillance system (Krankenhaus Infektions Surveillance System). Am J Infect Control 2003; 31: 316-21.
7. Ansari F, Gray K, Nathwani D et al. Outcomes of an intervention to improve hospital antibiotic prescribing: Interrupted time series with segmented regression analysis. J Antimicrob Chemother 2003; 52 842-8.
8. Wagner AK, Soumerai SB, Zhang F et al. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002; 27: 299-309.
9. Comaglia G, Hryniewicz W, Jarlier V et al. European recommendations for antimicrobial resistance surveillance. Clin Microbiol Infect 2004; 10: 349-83.
10. Kollef MH, Micek ST. Strategies to prevent antimicrobial resistance in the intensive care unit. Crit Care Med 2005; 33: 1845-53.
11. Bergmans DC, Bonten MJ, Gaillard CA et al. Indications for antibiotic use in ICU patients: A one-year prospective surveillance. J Antimicrob Chemother 1997; 39: 527-35.
12. Anon. Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995. Am J Respir Crit Care Med 1996; 153: 1711-25.
13. Fagon JY, Chastre J, Wolff M et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med 2000; 132: 621-30.
14. Singh N, Rogers P, Atwood CW et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000; 162: 505-11.
15. Lepper PM, Grusa E, Reichl H et al. Consumption of imipenem correlates with β-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002; 46: 2920-5.
16. Livermore DM. The impact of carbapenemases on antimicrobial development and therapy. Curr Opin Investig Drugs 2002; 3: 218-24.
17. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: Our worst nightmare? Clin Infect Dis 2002; 34: 634-40.
18. Meyer E, Schwab F, Jonas D et al. Temporal changes in bacterial resistance in German intensive care units, 2001-2003: Data from the SARI (surveillance of antimicrobial use and antimicrobial resistance in intensive care units) project. J Hosp Infect 2005; 60: 348-52.
19. Meyer E, Schwab F, Jonas D et al. Surveillance of antimicrobial use and antimicrobial resistance in intensive care units (SARI): 1. Antimicrobial use in German intensive care units. Intensive Care Med 2004; 30: 1089-96.
20. Cook PP, Catrou PG, Christie JD et al. Reduction in broad-spectrum antimicrobial use associated with no improvement in hospital antibiogram. J Antimicrob Chemother 2004; 53: 853-9.